Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Pdl Biopharma Inc (PDLI) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 362,540
  • Shares Outstanding, K 165,540
  • Annual Sales, $ 590,450 K
  • Annual Income, $ 332,800 K
  • 36-Month Beta 0.55
  • Price/Sales 0.62
  • Price/Book 0.49

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.06 +1.94%
on 12/02/16
3.77 -44.30%
on 11/15/16
-1.02 (-32.69%)
since 11/02/16
3-Month
2.06 +1.94%
on 12/02/16
3.77 -44.30%
on 11/15/16
-0.89 (-29.77%)
since 09/02/16
52-Week
2.06 +1.94%
on 12/02/16
3.95 -46.84%
on 12/17/15
-1.51 (-41.83%)
since 12/02/15

Most Recent Stories

More News
Biotech Stocks Under Scanner -- PDL BioPharma, Intrexon, 22nd Century, and Marinus Pharma

Stock-Callers.com directs investors' attention to stocks in the Biotech space which are still valued more than 25% below their 2015 peak. According to analysts and investment bankers, a potential influx...

ARIAD (ARIA) Stock Up on Narrower-than-Expected Q3 Loss

ARIAD (ARIA) reported third-quarter 2016 loss of 14 cents per share, narrower than the Zacks Consensus Estimate of a loss of 19 cents and the year-ago loss of 29 cents. Higher U.S. Iclusig sales and lower...

PDL BioPharma (PDLI) Q3 Earnings Lag, Revenues Fall Y/Y

PDL BioPharma, Inc. (PDLI) reported adjusted earnings of 11 cents per share in the third quarter of 2016, missing the Zacks Consensus Estimate of 14 cents. Adjusted arnings also declined from the year-ago...

PDL BioPharma Announces Third Quarter 2016 Financial Results

PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the third quarter ended September 30, 2016 including:

PDL BioPharma to Announce Third Quarter 2016 Financial Results on November 3, 2016

PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its third quarter 2016 financial results for the period ended September 30, 2016, on Thursday, November...

Biotech Stocks on Investors' Radar -- Alexion Pharma, PDL BioPharma, BioCryst Pharma, and Cara Therapeutics

US markets went back to a bearish environment following Monday's bullish performance. On Tuesday, the NASDAQ Composite ended the trading session down 1.54%; the Dow Jones Industrial Average lost 1.09%;...

ARIAD (ARIA) Leukemia Drug Iclusig Gets Approval in Japan

ARIAD Pharmaceuticals Inc. (ARIA) announced that its partner Otsuka Pharmaceutical Co., Ltd. has gained approval from the Japanese Pharmaceuticals and Medical Devices Agency for leukemia drug, Iclusig....

Will PDL BioPharma (PDLI) Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in PDL BioPharma Inc (PDLI)

Forget Novavax, Buy These 4 Biotech Stocks Instead

Shares of Novavax, Inc. (NVAX) plunged around 82% in pre-market trading on Friday after the biopharmaceutical company announced a day before that its key vaccine candidate unexpectedly failed to meet the...

The Zacks Analyst Blog Highlights: Mylan, ANI Pharmaceuticals, Cambrex, PDL BioPharma and Innoviva

The Zacks Analyst Blog Highlights: Mylan, ANI Pharmaceuticals, Cambrex, PDL BioPharma and Innoviva

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital...

See More

Support & Resistance

2nd Resistance Point 2.31
1st Resistance Point 2.21
Last Price 2.10
1st Support Level 2.03
2nd Support Level 1.95

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.